Search

Steven M Chamow

from San Mateo, CA
Age ~72
Get Report
Also known as:
Steven Mark Chamow, Steven M Chamon, Steve Chamow, Judith Chamow, Steven W
Phone and address:
747 Laurelwood Dr, San Mateo, CA 94403
(650) 345-1825
Related to:
Barren ChamowEmily T Chamow, 40Herman ChamowEli H Raber, 44Noah Chamow, 37Judith A Chamow, 77Stephanie J Chamow, 76Alexis S Chamow, 50Lindsay F Chamow, 48
Connected to:
Todd N Chamoy, 48Brenda M Champ, 61Chelsea M Champ, 30Chia Champ, 45Crystal G Champ, 46Elaine Champ, 37Eleanor B Champ, 33Fred E Champ, 86Guy Champ, 61Horace A Champ, 67

Steven Chamow Phones & Addresses

  • 747 Laurelwood Dr, San Mateo, CA 94403 (650) 345-1825 (650) 345-1878 (650) 345-0297
  • Burlingame, CA
  • Fremont, CA

Resumes

Resumes

Steven Chamow Photo 1

President

View page
Location:
Van Nuys, CA
Industry:
Biotechnology
Work:
Avid Bioservices Jan 2011 - Nov 2016
Head, Technical Services
Aridis Pharmaceutical Jan 2011 - Nov 2016
Vice President of Development
Chamow & Associates Jan 2011 - Nov 2016
President
Intradigm Corporation Nov 2006 - May 2008
Senior Vice President
Genitope Dec 2004 - May 2006
Vice President
Education:
University of California, Davis 1978 - 1984
Doctorates, Doctor of Philosophy, Biochemistry University of California, Santa Cruz 1972 - 1975
Bachelors, Bachelor of Arts, Biology Van Nuys High School
Van Nuys Senior High
Skills:
Biopharmaceuticals
Biotechnology
Technology Transfer
Gmp
Protein Chemistry
Pharmaceutical Industry
Validation
Cell Culture
Drug Discovery
Lifesciences
Biochemistry
Clinical Development
Fda
Glp
Antibodies
V&V
Oncology
Molecular Biology
Drug Development
Medical Devices
Sop
Capa
Purification
Steven Chamow Photo 2

Steven Chamow

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
Steven Chamow
President
S. & J. CHAMOW, INC
Business Services at Non-Commercial Site
747 Laurelwood Dr, San Mateo, CA 94403
Steven Chamow
Ceramic Separations, LLC
Research & Development of Chromatography
747 Laurelwood Dr, San Mateo, CA 94403

Publications

Us Patents

Carbohydrate-Directed Cross-Linking Reagents

View page
US Patent:
6582928, Jun 24, 2003
Filed:
Mar 2, 2000
Appl. No.:
09/517876
Inventors:
Avi J. Ashkenazi - San Mateo CA
Steven M. Chamow - San Mateo CA
Timothy P. Kogan - Sugar Land TX
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
G01N 33567
US Classification:
435 721, 435960, 435974, 436503, 436546, 436811, 436829, 530408, 530409, 530812, 548545, 548546, 548547
Abstract:
The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.

Posterior Segment Drug Delivery

View page
US Patent:
8399006, Mar 19, 2013
Filed:
Jan 29, 2010
Appl. No.:
12/696678
Inventors:
Yair Alster - Palo Alto CA, US
Steven M. Chamow - San Mateo CA, US
Kathleen Cogan Farinas - Los Altos CA, US
K. Angela Macfarlane - Woodside CA, US
Cary J. Reich - Los Gatos CA, US
Michael Barrett - Cupertino CA, US
Randolph E. Campbell - Redwood City CA, US
Robert George - San Jose CA, US
Douglas Sutton - Pacifica CA, US
Assignee:
Forsight Vision4, Inc. - Menlo Park CA
International Classification:
A61M 37/00
A61M 31/00
US Classification:
424422, 604 612, 604506
Abstract:
A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side. Each of the openings on the first side can be connected to each of the openings on the second side with the plurality of interconnecting channels, such that the rate of release of the therapeutic agent can be substantially maintained when one or more of the openings is blocked, for example with particles, cells, bacteria or tissue when the device is implanted for an extended time. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device many comprise an expandable retention structure and an expandable reservoir, such that the device can be delivered from a lumen of a delivery device and expand when positioned in the patient.

Sustained Drug Delivery System

View page
US Patent:
8530189, Sep 10, 2013
Filed:
Apr 16, 2011
Appl. No.:
13/088354
Inventors:
Kathleen Cogan Farinas - Los Altos CA, US
Steven Chamow - San Mateo CA, US
International Classification:
C07K 19/00
C07K 4/12
C07K 14/00
C07K 16/22
C12P 21/02
A61K 39/00
A61K 38/10
US Classification:
435 691, 435 697, 4241851, 4241921, 4241931, 4241341, 4241451
Abstract:
A drug composition comprising a charged moiety coupled to a therapeutic compound is disclosed. The charged moiety is configured to interact with at least one type of component of opposite charge in a biological tissue to create an in situ depot for prolonged drug delivery. The biological tissue may be eye tissue or any tissue containing charged components.

Sustained Drug Delivery System

View page
US Patent:
8535681, Sep 17, 2013
Filed:
Oct 15, 2009
Appl. No.:
13/124654
Inventors:
Kathleen Cogan Farinas - Los Altos CA, US
Steven Chamow - San Mateo CA, US
International Classification:
A61K 39/00
A61K 39/44
A61K 39/395
A61K 38/10
A61K 38/08
C07K 19/00
C07K 16/22
C07K 4/12
C07K 14/00
US Classification:
4241921, 4241931, 4241851, 4241341, 4241451
Abstract:
A drug composition comprising a charged moiety coupled to a therapeutic compound is disclosed. The charged moiety is configured to interact with at least one type of component of opposite charge in a biological tissue to create an in situ depot for prolonged drug delivery. The biological tissue may be eye tissue or any tissue containing charged components. Further, a method of treating the human body is disclosed. The method is for introducing into a human body a drug composition comprising a charged moiety coupled to a therapeutic compound. Introduction may be through injection. A method of manufacturing a drug composition comprising a charged moiety coupled to a therapeutic compound is also disclosed.

System And Method For Stabilizing Antibodies With Histidine

View page
US Patent:
20040191243, Sep 30, 2004
Filed:
Dec 11, 2003
Appl. No.:
10/734606
Inventors:
Bei Chen - Fremont CA, US
Gerardo Zapata - San Mateo CA, US
Michael Mulkerrin - Hillsborough CA, US
Steven Chamow - San Mateo CA, US
International Classification:
A61K039/395
US Classification:
424/130100, 514/400000
Abstract:
Stabilized antibody formulations containing histidine are described. In addition, methods of stabilizing liquid formulations of antibodies using histidine are also described. Kits using histidine to stabilize histidine.

Heterobifunctional Polyethylene Glycol Reagents

View page
US Patent:
20110282093, Nov 17, 2011
Filed:
Nov 12, 2008
Appl. No.:
12/742423
Inventors:
Daniel E. Levy - San Mateo CA, US
Samuel Zalipsky - Redwood City CA, US
Steven M. Chamow - San Mateo CA, US
Assignee:
Intradigm Corporation - Palo Alto CA
International Classification:
C07C 317/08
US Classification:
560150
Abstract:
The invention relates to heterobifunctional polyethylene glycol reagents, methods of producing them and methods of using them.

Posterior Segment Drug Delivery

View page
US Patent:
20130204209, Aug 8, 2013
Filed:
Mar 15, 2013
Appl. No.:
13/831695
Inventors:
Yair Alster - Menlo Park CA, US
Steven M. Chamow - Menlo Park CA, US
Kathleen Cogan Farinas - Menlo Park CA, US
K. Angela Macfarlane - Menlo Park CA, US
Cary J. Reich - Menlo Park CA, US
Michael Barrett - Menlo Park CA, US
Randolph E. Campbell - Menlo Park CA, US
Robert George - Menlo Park CA, US
Douglas Sutton - Menlo Park CA, US
International Classification:
A61F 9/00
US Classification:
60428802
Abstract:
A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.

Therapeutic Agent Formulations For Implanted Devices

View page
US Patent:
20140031769, Jan 30, 2014
Filed:
Nov 18, 2011
Appl. No.:
13/988298
Inventors:
Yair Alster - Menlo Park CA, US
Steven M. Chamow - Menlo Park CA, US
Kathleen Cogan Farinas - Menlo Park CA, US
K. Angela MacFarlane - Menlo Park CA, US
Cary J. Reich - Menlo Park CA, US
Randolph E. Campbell - Menlo Park CA, US
Signe Erickson - Menlo Park CA, US
Blaine Bueche - Menlo Park CA, US
Assignee:
ForSight Vision4, Inc. - Menlo Park CA
International Classification:
A61F 9/00
US Classification:
604294
Abstract:
An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.
Control profile
Steven M Chamow from San Mateo, CA, age ~72 Get Report